Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
AnaptysBio (ANAB), a clinical-stage biotechnology company specializing in innovative immunology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Daniel Faga, the company's president and chief executive officer, will deliver a presentation on Tuesday, January 14, 2025, at 4:30 PM PT / 7:30 PM ET.
The presentation will be accessible via live webcast through the investor section of the Anaptys website. Interested parties can access the webcast at http://ir.anaptysbio.com/events, and a replay will remain available for a minimum of 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – ANAB
On the day this news was published, ANAB declined 3.07%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days following the event.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical development. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch AnaptysBio's J.P. Morgan Healthcare Conference presentation?
How long will the replay of ANAB's J.P. Morgan Healthcare Conference presentation be available?
Who will be presenting for AnaptysBio at the 2025 J.P. Morgan Healthcare Conference?
What is AnaptysBio's primary business focus as presented at the J.P. Morgan Conference?
